Using AI, deep learning to fight aging

A Baltimore-based company is utilizing the power of artificial intelligence (AI) and deep learning to advance drug discovery, biomarker development and aging research.

Leveraging advanced AI, Insilico Medicine aims to use bioinformatics, research and development to extend patient lives.

“You have to look at the number of quality years of life you’re adding. If you include every individual on the planet, and you are adding one year of quality life to each of them, you’re generating 7.5 billion quality-adjusted life years,” said founder and CEO Alex Zhavoronkov, PhD. “That is the most altruistic decision to make. So if you go after aging, you are affecting the quality of life for everyone on the planet. The benefit of aging research generates the most benefit to society as a whole. If I can personally give one year of quality life to everyone, my life was very well spent.”

Read the full story from Forbes below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.